转自：证券时报网

　　北京首钢朗泽科技股份有限公司向港交所主板提交上市申请，国泰君安国际为独家保荐人。首钢朗泽自2011年成立以来，深耕全球CCUS行业，利用合成生物技术商业化生产低碳产品，包括乙醇和微生物蛋白。公司实现了全球首套利用工业尾气生产乙醇及微生物蛋白的工业化装置，并在中国成功运营四套规模化生产设施。首钢朗泽的乙醇可用于车用燃料、SAF等，微生物蛋白产品营养性优于传统蛋白，提供绿色环保的蛋白生产方案。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.